JP2017527541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527541A5 JP2017527541A5 JP2017505102A JP2017505102A JP2017527541A5 JP 2017527541 A5 JP2017527541 A5 JP 2017527541A5 JP 2017505102 A JP2017505102 A JP 2017505102A JP 2017505102 A JP2017505102 A JP 2017505102A JP 2017527541 A5 JP2017527541 A5 JP 2017527541A5
- Authority
- JP
- Japan
- Prior art keywords
- cd45rc
- antibody
- patient
- monoclonal antibody
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000735 allogeneic effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009386 Experimental Arthritis Diseases 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010023439 Kidney transplant rejection Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010024715 Liver transplant rejection Diseases 0.000 claims 1
- 206010051604 Lung transplant rejection Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000013633 acquired hemophilia Diseases 0.000 claims 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306231.3 | 2014-08-01 | ||
| EP14306231 | 2014-08-01 | ||
| PCT/EP2015/067707 WO2016016442A1 (en) | 2014-08-01 | 2015-07-31 | An anti-cd45rc antibody for use as drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219654A Division JP7015820B2 (ja) | 2014-08-01 | 2019-12-04 | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527541A JP2017527541A (ja) | 2017-09-21 |
| JP2017527541A5 true JP2017527541A5 (https=) | 2018-06-14 |
| JP6692343B2 JP6692343B2 (ja) | 2020-05-13 |
Family
ID=51302957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505102A Active JP6692343B2 (ja) | 2014-08-01 | 2015-07-31 | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 |
| JP2019219654A Active JP7015820B2 (ja) | 2014-08-01 | 2019-12-04 | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219654A Active JP7015820B2 (ja) | 2014-08-01 | 2019-12-04 | 薬物としての使用のための抗ｃｄ４５ｒｃ抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170226209A1 (https=) |
| EP (1) | EP3174902B1 (https=) |
| JP (2) | JP6692343B2 (https=) |
| ES (1) | ES2726645T3 (https=) |
| WO (1) | WO2016016442A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3174902B1 (en) * | 2014-08-01 | 2019-04-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An anti-cd45rc antibody for use as drug |
| HK1249534A1 (zh) | 2015-04-06 | 2018-11-02 | 哈佛大学校长及研究员协会 | 用於非清髓性预处理的组合物和方法 |
| CN109641051A (zh) | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| MX395639B (es) | 2017-01-20 | 2025-03-25 | Heidelberg Pharma Res Gmbh | Composiciones y métodos para el agotamiento de células cd137+. |
| EP3498293A1 (en) * | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| EP3626265A1 (en) * | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| JP2022535527A (ja) * | 2019-06-04 | 2022-08-09 | マジェンタ セラピューティクス インコーポレイテッド | 自己免疫疾患を治療するための方法および組成物 |
| CA3168039A1 (en) * | 2020-02-18 | 2021-08-26 | Geoffrey O. GILLARD | Compositions and methods for allogeneic transplantation |
| CA3172120A1 (en) | 2020-03-20 | 2021-09-23 | Inserm (Institut De La Sante Et De La Recherche Medicale) | Chimeric antigen receptor specific for human cd45rc and uses thereof |
| WO2022060874A1 (en) * | 2020-09-15 | 2022-03-24 | City Of Hope | Ex vivo expansion of regulatory t cells for suppression of graft versus host disease |
| WO2023041717A1 (en) | 2021-09-16 | 2023-03-23 | Aboleris Pharma | Anti-human cd45rc binding domains and uses thereof |
| WO2023118608A1 (en) | 2021-12-23 | 2023-06-29 | Universität Basel | Discernible cell surface protein variants of cd45 for use in cell therapy |
| JP2026500540A (ja) | 2022-12-23 | 2026-01-07 | シメイオ セラピューティクス アーゲー | Ｃｄ４５を標的とする抗体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US877397A (en) | 1907-07-15 | 1908-01-21 | American Pulley Co | Reel. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US7476536B2 (en) | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| EP3174902B1 (en) | 2014-08-01 | 2019-04-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An anti-cd45rc antibody for use as drug |
-
2015
- 2015-07-31 EP EP15744591.7A patent/EP3174902B1/en active Active
- 2015-07-31 WO PCT/EP2015/067707 patent/WO2016016442A1/en not_active Ceased
- 2015-07-31 JP JP2017505102A patent/JP6692343B2/ja active Active
- 2015-07-31 ES ES15744591T patent/ES2726645T3/es active Active
- 2015-07-31 US US15/500,615 patent/US20170226209A1/en not_active Abandoned
-
2019
- 2019-12-04 JP JP2019219654A patent/JP7015820B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527541A5 (https=) | ||
| JP6716668B2 (ja) | リンパ組織に幹細胞および前駆細胞が結合することを阻害する組成および方法、ならびにリンパ組織の胚中心を再生させるための組成および方法 | |
| Khandelwal et al. | Bortezomib for refractory autoimmunity in pediatrics | |
| FI3556774T3 (fi) | Anti-cd40-vasta-aineita ja niiden käyttötapoja | |
| Pileggi et al. | Mesenchymal stromal (stem) cells to improve solid organ transplant outcome: lessons from the initial clinical trials | |
| Ceulemans et al. | The Leuven immunomodulatory protocol promotes T-regulatory cells and substantially prolongs survival after first intestinal transplantation | |
| SA04240497A (ar) | طرق لمعالجة اضطرابات حيث تكون فعالية عامل النخر الورمي ألفا ضارة وذلك بإعطاء جرعات علاجية منخفضة | |
| JP2014505056A5 (https=) | ||
| Helderman et al. | Immunosuppression: practice and trends | |
| ES2423481T3 (es) | Métodos de tratamiento de enfermedades autoinmunes | |
| CA2815542C (en) | Use of a spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is useful for preventing and/or treating multiple sclerosis | |
| US20060188505A1 (en) | Treatment of autism | |
| JP2016537380A5 (https=) | ||
| Liao et al. | Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review | |
| Schneeberger et al. | Immunosuppression and monitoring of rejection in hand transplantation | |
| Ratanabanangkoon | A quest for a universal plasma-derived antivenom against all elapid neurotoxic snake venoms | |
| KR20150063076A (ko) | 혈관 질환 및 이에 따른 합병증 치료 | |
| Murata | Prophylactic and therapeutic treatment of graft-versus-host disease in Japan | |
| Wobma et al. | Mesenchymal stromal cells: Getting ready for clinical primetime | |
| Zhao et al. | The off-label uses profile of tofacitinib in systemic rheumatic diseases | |
| Chang et al. | The impact of current immunosuppression strategies in renal transplantation on the field of reconstructive transplantation | |
| Tisdale et al. | HCT for nonmalignant disorders | |
| Morath et al. | Recent developments in desensitization of crossmatch-positive kidney transplant recipients | |
| Pession et al. | Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option? | |
| Lee et al. | ABO-incompatible kidney transplantation |